Another Oral Agent Demonstrates Clinical Improvement in Chronic Plaque Psoriasis

Although not yet FDA-approved, this drug uses a novel mechanism, and further research might yield a new oral agent.

Ponesimod, which selectively and reversibly modulates the sphingosine 1-phosphate (S1P) receptor 1 (S1PR1), has been suggested as treatment for chronic plaque psoriasis. It reduces lymphocytes in circulation without affecting their survival or activation. Drug half-life is 30 hours; it is essentially eliminated from the body 1 week after the last dose. In a new, manufacturer-funded, phase II, placebo-controlled study, researchers (3 employed by the manufacturer) compared effectiveness and safety of ponesimod (20 mg or 40 mg daily) in 326 patients with moderate chronic plaque psoriasis. Randomization occurred in a 1:2:2 ratio (placebo:20 mg:40 mg); the primary outcome was a 75% decrease at 16 weeks in scores on the psoriasis area and severit…

Reviewing Author

Jeffrey P. Callen, MD

Disclosures

Consultant / Advisory board XOMA; Eli Lilly; Celgene

Equity Various trust accounts

Editorial boards JAMA Dermatology; UpToDate

Leadership positions in professional societies Association of Professors of Dermatology (President-Elect)

Jeffrey P. Callen, MD

Disclosures

Consultant / Advisory board XOMA; Eli Lilly; Celgene

Equity Various trust accounts

Editorial boards JAMA Dermatology; UpToDate

Leadership positions in professional societies Association of Professors of Dermatology (President-Elect)

Another Oral Agent Demonstrates Clinical Improvement in Chronic Plaque Psoriasis

Topics

Reviewing Author